Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1131-1135

  Nolte, Florian ^a   Angelucci, Emanuele ^b   Beris, Photis ^c   Macwhannell, Alan ^d   Selleslag, Dominik ^e   Schumann, Christiane ^a   Xicoy, Blanca ^f   Almeida, Antonio ^g   Guerci Bresler, Agnés ^h   Sliwa, Thamer ⁱ   Muus, Petra ^j   Porter, John ^k   Hofmann, Wolf K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Ospedale Oncologico A Businco   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d NEW CROSS HOSPITAL   (United Kingdom)

^e General Hospital St Jan   (Belgium)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g Instituto Portugues de Oncologia de Lisboa   (Portugal)

^h CHU NANCY BRABOIS   (France)

ⁱ Hietzing Hospital 5Med   (Austria)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Chelation; Deferasirox; Gastrointestinal disturbances; Iron overload; Myelodysplastic syndrome; Transfusion

Indexed keywords

DEFERASIROX;

ABDOMINAL PAIN; ARTICLE; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THALASSEMIA; VOMITING;

BENZOIC ACIDS; CHELATION THERAPY; GASTROINTESTINAL DISEASES; HUMANS; IRON CHELATING AGENTS; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; TRIAZOLES;

EID: 80051475539     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.013     Document Type: Article

References (20)

1. Germing U., Strupp C., Kundgen A., et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004, 89:905-910.
2. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
3. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
4. Modell B., Khan M., Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia register. Lancet 2000, 355:2051-2052.
5. Arboretti R., Tognoni G., Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur. J. Clin Pharmacol. 2001, 56:915-922.
6. Cappellini M.D., Bejaoui M., Agaoglu L., et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin. Ther. 2007, 29:909-917.
7. Galanello R., Piga A., Cappellini M.D., et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J. Clin. Pharmacol. 2008, 48:428-435.
8. Waldmeier F., Bruin G.J., Glaenzel U., et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab. Dispos. 2010, 38:808-816.
9. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol. 2008, 83:858-861.
10. Jensen P.D., Heickendorff L., Pedersen B., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br. J. Haematol. 1996, 94:288-299.
11. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003, 101:4632-4639.
12. Kersten M.J., Lange R., Smeets M.E., et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann. Hematol. 1996, 73:247-252.
13. Porter J., Galanello R., Saglio G., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol. 2008, 80:168-176.
14. Metzgeroth G., Dinter D., Schultheis B., et al. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann. Hematol. 2009, 88:301-310.
15. List A.F., Baer M.R., Steensma D., et al. Iron chelation with deferasirox (Exjade(R)) improves iron burden in patients with Myelodysplastic Syndromes (MDS). ASH Ann. Meeting Abstracts 2008, 112:634.
16. Gattermann N., Finelli C., Porta M.D., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk. Res. 2010, 34:1143-1150.
17. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 2005, 23:7594-7603.
18. Rose C., Brechignac S., Vassilief D., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk. Res. 2010.
19. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
20. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.